Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
OMIC Singular Genomics
2.450-0.340-12.19%
Close
02/08 16:00 ET
2.4500.0000.00%
Post Mkt Price 02/08 17:01 ET
High
2.914
Open
2.730
Turnover
532.25K
Low
2.400
Pre Close
2.790
Volume
194.57K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Singular Genomics Launches Max Read™ Kits for Single Cell Sequencing on the G4 at AGBT
- New next-generation sequencing kit maximizes throughput and decreases the cost for single cell experiments - - Company announces increased quality and throughput specifications of the G4 Sequencing
Singular Genomics Showcases New G4 Sequencing Platform Data With 11 Industry-Leading Genomics Partners at AGBT
SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians,
Singular Genomics Joins the 10x Genomics Compatible Partner Program
– Demonstrates compatibility of the G4 Sequencing Platform with 10x Genomics Single Cell Applications – SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a
Head-To-Head Survey: Singular Genomics Systems (NASDAQ:OMIC) and Nautilus Biotechnology (NASDAQ:NAUT)
Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two
Analyzing Akoya Biosciences (NASDAQ:AKYA) and Singular Genomics Systems (NASDAQ:OMIC)
Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Akoya Biosciences (NASDAQ:AKYA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two bus
Singular Genomics Systems Reports Q4 Instrument Shipments
07:12 AM EST, 01/09/2023 (MT Newswires) -- Singular Genomics Systems (OMIC) on Monday said it shipped five G4 instruments in Q4, which made the company approximately $700,000 in preliminary unaudited
Singular Genomics Reports The Company Shipped Five G4 Instruments Through December 31, 2022 And Recognized ~$700K In Preliminary Unaudited Revenue During Q4
Singular Genomics Reports The Company Shipped Five G4 Instruments Through December 31, 2022 And Recognized ~$700K In Preliminary Unaudited Revenue During Q4
Singular Genomics Systems Sees 4Q Rev $700,000 >OMIC
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians,
Singular Genomics Systems (NASDAQ:OMIC) Stock Price Up 2%
Singular Genomics Systems, Inc. (NASDAQ:OMIC – Get Rating)'s share price rose 2% during trading on Tuesday . The company traded as high as $2.12 and last traded at $2.05. Approximately 73,542 shares
Company Overview
More
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.
CEO： Mr. Andrew Spaventa
Market： NASDAQ
Listing Date： 05/27/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet